webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More
Small Molecule (API) Development

Small Molecule (API) Development

Small-Molecule-API-Development Pharmacology usually limits the term “small molecule” to a molecule that binds to a particular biological macromolecule and acts as an effector molecule, changing the activity or function of the target molecule. Small molecules have a variety of biological functions or applications, such as cell signaling molecules, drugs, agricultural pesticides and so on. These compounds can be natural (e.g. secondary metabolites) or artificial (e.g. antiviral drugs); they may be beneficial to diseases (e.g. drugs) or harmful (e.g. teratogens and carcinogens). Small molecules can be used as research tools to explore biological functions, as well as pioneers in the development of new therapeutic drugs.

BOC Science brings over years of experience in the small molecule development and manufacturing market, where we have considerable experience with a repertoire of chemical reactions and transformations:

  • Hydrogenations
  • Oxidations
  • Cryogenics
  • Friedal-Crafts
  • Chiral Synthesis
  • Organometallics
  • Amination
  • Cyanation
  • Carbonylation
  • Diels-Alder
  • Acylation
  • Phosphorylation
  • Bio-Catalysis

Our Advantages

In cooperation with us, you can also seamlessly coordinate the development and production of your small molecular APIs and finished drugs. Our API development services can be combined with our complete family of drug product services, including pre-prescription screening, clinical development and commercial supply-both of which we are world leaders in. Large or small, at each stage, you will gain the advantage of seamless collaboration between our sites, teams, and operations.

Drive Small Molecule API Development with BOC Sciences

BOC Sciences delivers robust API development services including process design, impurity control, and scale-up strategies to ensure high purity and consistent manufacturing.

Submit your inquiry to request a custom solution.

References

  1. Chaplin, D. J., Horsman, M. R., & Siemann, D. W. (2006). Current development status of small-molecule vascular disrupting agents. Current opinion in investigational drugs (London, England: 2000), 7(6), 522-528.
  2. Woodley, J. M. (2018). Innovative process development and production concepts for small-molecule API manufacturing. Computer Aided Chemical Engineering, 41, 67-84.
Our Highlights
  • Advanced computer aided technology
  • Custom synthesis for small molecules
  • One-stop, systematic services
  • Experienced technical team
  • Technical support, quality assurance
Online Inquiry
Verification code